Hyperphosphatemia
Clinical trials for Hyperphosphatemia explained in plain language.
Never miss a new study
Get alerted when new Hyperphosphatemia trials appear
Sign up with your email to follow new studies for Hyperphosphatemia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a daily capsule tame dangerous phosphorus levels in dialysis patients?
Disease control Recruiting nowThis study follows adults with chronic kidney disease who are on dialysis and starting the phosphate binder Nephoxil for high blood phosphorus. Researchers track patients for 48 weeks to see how many reach a target phosphorus level of 3.5 to 5.5 mg/dL, using either a low or stand…
Matched conditions: HYPERPHOSPHATEMIA
Sponsor: LG Chem • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can lowering phosphate save hearts in kidney failure?
Disease control Recruiting nowThis trial asks whether aggressively lowering blood phosphate levels in people with end-stage kidney disease on dialysis can reduce heart attacks, strokes, and death. Participants are randomly assigned to either a liberal phosphate target or an intensive target aimed at normal le…
Matched conditions: HYPERPHOSPHATEMIA
Sponsor: The University of Queensland • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New pill could help dialysis patients control dangerous phosphate levels
Disease control Recruiting nowThis study tests a new drug called AP306 in 168 adults on maintenance hemodialysis who have high phosphate levels (hyperphosphatemia). Participants take one of several fixed doses of AP306 or a placebo daily for 8 weeks. The main goal is to see if AP306 safely lowers blood phosph…
Matched conditions: HYPERPHOSPHATEMIA
Phase 2 • Sponsor: R1 Therapeutics • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New hope for dialysis patients: drug AP301 targets dangerous phosphate levels
Disease control Recruiting nowThis phase 3 trial tests whether AP301, a drug taken with meals, can safely lower high blood phosphate in people on kidney dialysis. About 264 participants will receive either AP301 or a low-dose version for 8 weeks, then all get AP301 for 24 weeks. The goal is to see if AP301 he…
Matched conditions: HYPERPHOSPHATEMIA
Phase 3 • Sponsor: Alebund Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Massive study aims to crack the code on Kids' medications
Knowledge-focused Recruiting nowThis study is collecting blood and other samples from 5,000 children and young adults (under 21) who are already taking certain medications as part of their regular care. The goal is to understand how these drugs move through and affect children's bodies, so doctors can prescribe…
Matched conditions: HYPERPHOSPHATEMIA
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC